The misuse of antibiotics in industrial agriculture is accelerating the rise of drug-resistant "superbugs," now responsible for 1.14 million deaths globally each year — a figure projected to rise to 8.22 million by 2050 if current trends continue. Despite these dire warnings, the U.S. Food and Drug Administration (FDA) continues to prioritize corporate interests over public health, gutting oversight while appointing industry insiders to key regulatory positions.
The World Health Organization (WHO) has repeatedly warned of a looming "post-antibiotic era" where common infections could become fatal. Yet, 70% of medically important antibiotics in the U.S. are used in livestock, often not to treat disease but to promote growth and compensate for the filthy, overcrowded conditions of factory farms. This reckless practice allows bacteria to evolve resistance, rendering life-saving drugs ineffective for humans.
FDA lay offs key staff overseeing veterinary medicine, leaving Big Ag unchecked
In April 2024, the Department of Health and Human Services (HHS) executed mass layoffs at the FDA, eliminating over 140 positions, including veterinarians critical to monitoring antibiotic misuse in agriculture. Among those dismissed was the chief veterinary officer, a key figure in enforcing antibiotic regulations.
Delcianna Winders, director of the Animal Law and Policy Institute, condemned the move: "It seems less likely than ever that progress on this ticking time bomb will be made under the current administration."
The layoffs coincided with the appointment of Timothy Schell, a former executive at Elanco Animal Health — a major producer of livestock antibiotics — as the acting director of the FDA’s Center for Veterinary Medicine (CVM). Critics argue that Schell’s ties to industry ensure continued regulatory inaction.
Andrew deCoriolis of Farm Forward stated: "It’s pretty hard to take seriously the idea that FDA is going to curb antibiotic use on farms when they appoint a former drug company lobbyist as the chief regulator."
Former drug lobbyist appointed to lead FDA’s veterinary division, signaling surrender to corporate interests...The revolving door between regulators and industry has long undermined public trust in the FDA. Schell’s appointment follows a pattern of regulatory capture, where agencies tasked with protecting consumers instead serve corporate agendas.
Under Schell’s leadership, the FDA has continued to rely on voluntary guidelines for antibiotic use, allowing drugmakers and agribusiness to self-regulate. Meanwhile, the agency’s data-collection program — funded by industry — has been dismissed as "toothless theater" by critics, as it relies on self-reported data from the very companies profiting from antibiotic overuse.
U.S. blocks global efforts to reduce farm antibiotics, prioritizing profits over public health
In September 2024, the U.S. joined a United Nations pledge to reduce farm antibiotic use by 2030—but actively blocked binding targets, ensuring no enforceable action. This move aligns with the interests of Big Pharma and industrial agriculture, which profit from the status quo.
A 2024 Lancet report on antimicrobial resistance (AMR) revealed alarming trends:
- MRSA (Methicillin-resistant Staphylococcus aureus) deaths have doubled since 1990.
- Carbapenem-resistant bacteria now kill over 1 million people annually.
- By 2050, antibiotic resistance could surpass cancer as a leading cause of death.
Despite these warnings, the FDA’s policies remain weak and industry-friendly, with no meaningful restrictions on the most dangerous antibiotics. The stakes could not be higher. If antibiotic resistance continues unchecked, routine medical procedures—from surgeries to chemotherapy — could become deadly due to untreatable infections. Yet, the FDA’s actions suggest business as usual, even as the crisis escalates. Robert F. Kennedy Jr. and Dr. Martin Makary, both vocal critics of antibiotic misuse, were seen as potential reformers when appointed to leadership roles at HHS and the FDA. However, the recent layoffs and industry-friendly appointments indicate that real change is far off.
What can be done?
- Support efforts to hold FDA officials and drug company executives accountable for their role in this public health crisis.
- Demand real FDA reform by contacting political representatives and advocating for binding antibiotic restrictions.
- Spread awareness by sharing this information and supporting independent journalism that exposes corporate malfeasance.
For the latest on these trends, check out Superbugs.News.
Sources include:
Please contact us for more information.